Actualités Palantir CDR - PLTR | Actions Toronto Stock Exchange

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

U.S. National Institutes of Health Recommend to Expand Its Scope of Research in the Development of Pluristem's PLX-RAD Cells fo

HAIFA, Israel, July 18, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a...

Pluristem Completes Enrollment for Phase I/II Muscle Injury Trial

HAIFA, Israel, July 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a...

Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells

HAIFA, Israel, July 8, 2013 (GLOBE NEWSWIRE) -- On the heels of announcing its strategic partnership agreement...

Pluristem Enters Into Strategic Partnership and Licensing Agreement With Cha Bio&Diostech for the Development and Commercializa

HAIFA, Israel, June 26, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today...

Pluristem's Preclinical Results for Its PLX-RAD Cells Published in the Journal PLOS ONE

HAIFA, Israel, June 20, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a...

Pluristem Provides Update on Clinical Status of IC Trials

HAIFA, Israel, June 19, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a...

Pluristem to Deliver Two Presentations During Israel's Largest Biotech Conference: IATI-BioMed

HAIFA, Israel, June 10, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a...

Pluristem to Receive Clinical-hold Notice From the U.S. FDA

HAIFA, Israel, June 4, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a...

Pluristem to Present at FDA Symposium

HAIFA, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a...

Pluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nucl

HAIFA, Israel, May 22, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Palantir CDR (PLTR)

Outils de qualité professionnelle, pour des investisseurs individuels.

Palantir CDR (PLTR) Actualités

U.S. National Institutes of Health Recommend to Expand Its Scope of Research in the Development of Pluristem's PLX-RAD Cells fo

Pluristem Completes Enrollment for Phase I/II Muscle Injury Trial

Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells

Pluristem Enters Into Strategic Partnership and Licensing Agreement With Cha Bio&Diostech for the Development and Commercializa

Pluristem's Preclinical Results for Its PLX-RAD Cells Published in the Journal PLOS ONE

Pluristem Provides Update on Clinical Status of IC Trials

Pluristem to Deliver Two Presentations During Israel's Largest Biotech Conference: IATI-BioMed

Pluristem to Receive Clinical-hold Notice From the U.S. FDA

Pluristem to Present at FDA Symposium

Pluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nucl

Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia

Pluristem Develops PLX-RAD Cells for Use in Hematology

Pluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013

Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension

Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Palantir CDR (PLTR)

Outils de qualité professionnelle, pour des investisseurs individuels.

Palantir CDR (PLTR) Actualités

U.S. National Institutes of Health Recommend to Expand Its Scope of Research in the Development of Pluristem's PLX-RAD Cells fo

Pluristem Completes Enrollment for Phase I/II Muscle Injury Trial

Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells

Pluristem Enters Into Strategic Partnership and Licensing Agreement With Cha Bio&Diostech for the Development and Commercializa

Pluristem's Preclinical Results for Its PLX-RAD Cells Published in the Journal PLOS ONE

Pluristem Provides Update on Clinical Status of IC Trials

Pluristem to Deliver Two Presentations During Israel's Largest Biotech Conference: IATI-BioMed

Pluristem to Receive Clinical-hold Notice From the U.S. FDA

Pluristem to Present at FDA Symposium

Pluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nucl

Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia

Pluristem Develops PLX-RAD Cells for Use in Hematology

Pluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013

Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension

Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités